Hepatitis B Vaccine Market Size, Industry Share and Global Forecast 2025 - 2033
Description
The Global Hepatitis B Vaccine Market Size accounted for USD 6.13 Billion in 2024 and is estimated to achieve a market size of USD 10.08 Billion by 2033 growing at a CAGR of 5.8% from 2025 to 2033.
The global Hepatitis B vaccine market plays a pivotal role in controlling and preventing Hepatitis B virus (HBV) infections, which continue to pose significant public health challenges worldwide. Hepatitis B is a viral infection that affects the liver, leading to conditions such as cirrhosis, liver cancer, and acute liver failure, making vaccination a critical tool for public health systems globally. The introduction of the Hepatitis B vaccine has contributed to a considerable reduction in the global prevalence of HBV infections, especially in regions with high endemicity. As the demand for effective vaccination increases due to rising awareness and a focus on prevention, the Hepatitis B vaccine market is expanding, driven by factors such as increasing vaccination coverage, government initiatives, and advancements in vaccine development technologies.
Hepatitis B Vaccine Market Segmentation
The worldwide market for hepatitis B vaccine is split based on technology, doses, age, end-user, and geography.
Hepatitis B Vaccine Market By Type
Single Antigen Hepatitis B Vaccine
Combination Vaccines
Hepatitis B Vaccine Market By Doses
3-Dose Schedule
2-Dose Schedule
Alternate Schedule
Hepatitis B Vaccine Age
Pediatrics
Adults
Hepatitis B Vaccine End-user
Hospitals
Clinics
Others
Hepatitis B Vaccine Market Regional Outlook
North America
U.S.
Canada
Europe
U.K.
Germany
France
Spain
Rest of Europe
Asia-Pacific
India
Japan
China
Australia
South Korea
Rest of Asia-Pacific
Latin America
Brazil
Mexico
Rest of LATAM
The Middle East & Africa
South Africa
GCC Countries
Rest of the Middle East & Africa (ME&A)
Hepatitis B Vaccine Market Players
Some of the top hepatitis B vaccine companies offered in our report includes Dynavax Technologies, Novartis AG, Emergent Biosolutions, Beijing Minhai Biotechnology, GlaxoSmithKline Biologicals, Merck & Co, Inc, CSL Ltd, Sinovac Biotech, Pfizer Inc., Sanofi Pasteur, Serum Institute of India, and Emergent Biosolutions.
How Acumen Research and Consulting Reserch Study of helps clients in their decision making:
Creating strategies for new product development
Supporting & Adjust Investment/business decisions
Benchmark and judge own competitiveness
Aiding in the business planning process
Serving as a credible, independent check on company internal forecasts
Supporting acquisition strategies
The global Hepatitis B vaccine market plays a pivotal role in controlling and preventing Hepatitis B virus (HBV) infections, which continue to pose significant public health challenges worldwide. Hepatitis B is a viral infection that affects the liver, leading to conditions such as cirrhosis, liver cancer, and acute liver failure, making vaccination a critical tool for public health systems globally. The introduction of the Hepatitis B vaccine has contributed to a considerable reduction in the global prevalence of HBV infections, especially in regions with high endemicity. As the demand for effective vaccination increases due to rising awareness and a focus on prevention, the Hepatitis B vaccine market is expanding, driven by factors such as increasing vaccination coverage, government initiatives, and advancements in vaccine development technologies.
Hepatitis B Vaccine Market Segmentation
The worldwide market for hepatitis B vaccine is split based on technology, doses, age, end-user, and geography.
Hepatitis B Vaccine Market By Type
Single Antigen Hepatitis B Vaccine
Combination Vaccines
Hepatitis B Vaccine Market By Doses
3-Dose Schedule
2-Dose Schedule
Alternate Schedule
Hepatitis B Vaccine Age
Pediatrics
Adults
Hepatitis B Vaccine End-user
Hospitals
Clinics
Others
Hepatitis B Vaccine Market Regional Outlook
North America
U.S.
Canada
Europe
U.K.
Germany
France
Spain
Rest of Europe
Asia-Pacific
India
Japan
China
Australia
South Korea
Rest of Asia-Pacific
Latin America
Brazil
Mexico
Rest of LATAM
The Middle East & Africa
South Africa
GCC Countries
Rest of the Middle East & Africa (ME&A)
Hepatitis B Vaccine Market Players
Some of the top hepatitis B vaccine companies offered in our report includes Dynavax Technologies, Novartis AG, Emergent Biosolutions, Beijing Minhai Biotechnology, GlaxoSmithKline Biologicals, Merck & Co, Inc, CSL Ltd, Sinovac Biotech, Pfizer Inc., Sanofi Pasteur, Serum Institute of India, and Emergent Biosolutions.
How Acumen Research and Consulting Reserch Study of helps clients in their decision making:
Creating strategies for new product development
Supporting & Adjust Investment/business decisions
Benchmark and judge own competitiveness
Aiding in the business planning process
Serving as a credible, independent check on company internal forecasts
Supporting acquisition strategies
Table of Contents
250 Pages
- CHAPTER 1 Industry Overview of Hepatitis B Vaccine Market
- 1.1 Definition and Scope
- 1.2 Summary
- CHAPTER 2 Research Approach
- 2.1 Methodology
- 2.2 Data Source
- CHAPTER 3 Market Dynamics And Competition Analysis
- 3.1 Market Drivers
- 3.2 Restraints and Challenges
- 3.3 Growth Opportunities
- 3.4 Porter’s Five Forces Analysis
- 3.4.1 Bargaining Power of Suppliers
- 3.4.2 Bargaining Power of Buyers
- 3.4.3 Threat of Substitute
- 3.4.4 Threat of New Entrants
- 3.4.5 Degree of Competition
- 3.5 Market Concentration Ratio and Market Maturity Analysis of Hepatitis B Vaccine Market
- 3.5.1 Go To Market Strategy
- 3.5.1.1 Introduction
- 3.5.1.2 Growth
- 3.5.1.3 Maturity
- 3.5.1.4 Saturation
- 3.5.1.5 Possible Development
- 3.6 Technological Roadmap for Hepatitis B Vaccine Market
- 3.7 Value Chain Analysis
- 3.7.1 List of Key Manufacturers
- 3.7.2 List of Customers
- 3.7.3 Level of Integration
- 3.8 Cost Structure Analysis
- 3.8.1 Price Trend of Key Raw Materials
- 3.8.2 Raw Material Suppliers
- 3.8.3 Proportion of Manufacturing Cost Structure
- 3.8.3.1 Raw Material
- 3.8.3.2 Labor Cost
- 3.8.3.3 Manufacturing Expense
- 3.9 Regulatory Compliance
- 3.10 Competitive Landscape, 2024
- 3.10.1 Player Positioning Analysis
- 3.10.2 Key Strategies Adopted By Leading Players
- CHAPTER 4 Manufacturing Plant Analysis
- 4.1 Manufacturing Plant Location and Establish Date of Major Manufacturers in 2024
- 4.2 R&D Status of Major Manufacturers in 2024
- CHAPTER 5 Hepatitis B Vaccine Market By Type
- 5.1 Introduction
- 5.2 Hepatitis B Vaccine Revenue By Type
- 5.2.1 Hepatitis B Vaccine Revenue (USD Billion) and Forecast, By Type, 2021-2033
- 5.2.2 Single Antigen Hepatitis B Vaccine
- 5.2.2.1 Single Antigen Hepatitis B Vaccine Market Revenue (USD Billion) and Growth Rate (%), 2021-2033
- 5.2.3 Combination Vaccines
- 5.2.3.1 Combination Vaccines Market Revenue (USD Billion) and Growth Rate (%), 2021-2033
- CHAPTER 6 Hepatitis B Vaccine Market By Doses
- 6.1 Introduction
- 6.2 Hepatitis B Vaccine Revenue By Doses
- 6.2.1 Hepatitis B Vaccine Revenue (USD Billion) and Forecast, By Doses, 2021-2033
- 6.2.2.3 Dose Schedule
- 6.2.2.1.3 Dose Schedule Market Revenue (USD Billion) and Growth Rate (%), 2021-2033
- 6.2.3.2 Dose Schedule
- 6.2.3.1.2 Dose Schedule Market Revenue (USD Billion) and Growth Rate (%), 2021-2033
- 6.2.4 Alternate Schedule
- 6.2.4.1 Alternate Schedule Market Revenue (USD Billion) and Growth Rate (%), 2021-2033
- CHAPTER 7 Hepatitis B Vaccine Market By Age
- 7.1 Introduction
- 7.2 Hepatitis B Vaccine Revenue By Age
- 7.2.1 Hepatitis B Vaccine Revenue (USD Billion) and Forecast, By Age, 2021-2033
- 7.2.2 Pediatrics
- 7.2.2.1 Pediatrics Market Revenue (USD Billion) and Growth Rate (%), 2021-2033
- 7.2.3 Adults
- 7.2.3.1 Adults Market Revenue (USD Billion) and Growth Rate (%), 2021-2033
- CHAPTER 8 Hepatitis B Vaccine Market By End-user
- 8.1 Introduction
- 8.2 Hepatitis B Vaccine Revenue By End-user
- 8.2.1 Hepatitis B Vaccine Revenue (USD Billion) and Forecast, By End-user, 2021-2033
- 8.2.2 Hospitals
- 8.2.2.1 Hospitals Market Revenue (USD Billion) and Growth Rate (%), 2021-2033
- 8.2.3 Clinics
- 8.2.3.1 Clinics Market Revenue (USD Billion) and Growth Rate (%), 2021-2033
- 8.2.4 Others
- 8.2.4.1 Others Market Revenue (USD Billion) and Growth Rate (%), 2021-2033
- CHAPTER 9 North America Hepatitis B Vaccine Market By Country
- 9.1 North America Hepatitis B Vaccine Market Overview
- 9.2 U.S.
- 9.2.1 U.S. Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 9.2.2 U.S. Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 9.2.3 U.S. Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 9.2.4 U.S. Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End-Use, 2021-2033
- 9.3 Canada
- 9.3.1 Canada Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 9.3.2 Canada Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 9.3.3 Canada Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 9.3.4 Canada Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 9.4 North America PEST Analysis
- CHAPTER 10 Europe Hepatitis B Vaccine Market By Country
- 10.1 Europe Hepatitis B Vaccine Market Overview
- 10.2 U.K.
- 10.2.1 U.K. Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 10.2.2 U.K. Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 10.2.3 U.K. Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 10.2.4 U.K. Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 10.3 Germany
- 10.3.1 Germany Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 10.3.2 Germany Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 10.3.3 Germany Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 10.3.4 Germany Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 10.4 France
- 10.4.1 France Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 10.4.2 France Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 10.4.3 France Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 10.4.4 France Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 10.5 Spain
- 10.5.1 Spain Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 10.5.2 Spain Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 10.5.3 Spain Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 10.5.4 Spain Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 10.6 Rest of Europe
- 10.6.1 Rest of Europe Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 10.6.2 Rest of Europe Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 10.6.3 Rest of Europe Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 10.6.4 Rest of Europe Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 10.7 Europe PEST Analysis
- CHAPTER 11 Asia Pacific Hepatitis B Vaccine Market By Country
- 1.1 Asia Pacific Hepatitis B Vaccine Market Overview
- 11.2 China
- 11.2.1 China Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 11.2.2 China Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 11.2.3 China Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 11.2.4 China Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 11.3 Japan
- 11.3.1 Japan Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 11.3.2 Japan Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 11.3.3 Japan Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 11.3.4 Japan Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 11.4 India
- 11.4.1 India Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 11.4.2 India Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 11.4.3 India Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 11.4.4 India Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 11.5 Australia
- 11.5.1 Australia Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 11.5.2 Australia Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 11.5.3 Australia Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 11.5.4 Australia Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 11.6 South Korea
- 11.6.1 South Korea Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 11.6.2 South Korea Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 11.6.3 South Korea Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 11.6.4 South Korea Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 11.7 Rest of Asia-Pacific
- 11.7.1 Rest of Asia-Pacific Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 11.7.2 Rest of Asia-Pacific Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 11.7.3 Rest of Asia-Pacific Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 11.7.4 Rest of Asia-Pacific Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 11.8 Asia Pacific PEST Analysis
- CHAPTER 12 Latin America Hepatitis B Vaccine Market By Country
- 12.1 Latin America Hepatitis B Vaccine Market Overview
- 12.2 Brazil
- 12.2.1 Brazil Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 12.2.2 Brazil Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 12.2.3 Brazil Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 12.2.4 Brazil Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 12.3 Mexico
- 12.3.1 Mexico Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 12.3.2 Mexico Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 12.3.3 Mexico Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 12.3.4 Mexico Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 12.4 Rest of Latin America
- 12.4.1 Rest of Latin America Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 12.4.2 Rest of Latin America Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 12.4.3 Rest of Latin America Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 12.4.4 Rest of Latin America Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 12.5 Latin America PEST Analysis
- CHAPTER 13 Middle East & Africa Hepatitis B Vaccine Market By Country
- 13.1 Middle East & Africa Hepatitis B Vaccine Market Overview
- 13.2 GCC
- 13.2.1 GCC Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 13.2.2 GCC Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 13.2.3 Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 13.2.4 Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 13.3 South Africa
- 13.3.1 South Africa Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 13.3.2 South Africa Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 13.3.3 South Africa Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 13.3.4 South Africa Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 13.4 Rest of Middle East & Africa
- 13.4.1 Rest of Middle East & Africa Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 13.4.2 Rest of Middle East & Africa Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 13.4.3. Rest of Middle East & Africa Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 13.4.4 Rest of Middle East & Africa Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 13.5 Middle East & Africa PEST Analysis
- CHAPTER 14 Player Analysis Of Hepatitis B Vaccine Market
- 14.1 Hepatitis B Vaccine Market Company Share Analysis
- 14.2 Competition Matrix
- 14.2.1 Competitive Benchmarking of key players by price, presence, market share, and R&D investment
- 14.2.2 New Product Launches and Product Enhancements
- 14.2.3 Mergers And Acquisition In Global Hepatitis B Vaccine Market
- 14.2.4 Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
- CHAPTER 15 Company Profile
- 15.1 Dynavax Technologies
- 15.1.1 Company Snapshot
- 15.1.2 Business Overview
- 15.1.3 Financial Overview
- 15.1.3.1 Revenue (USD Billion), 2024
- 15.1.3.2 Dynavax Technologies 2024 Hepatitis B Vaccine Business Regional Distribution
- 15.1.4 Product /Service and Specification
- 15.1.5 Recent Developments & Business Strategy
- 15.2 Novartis AG
- 15.3 Emergent Biosolutions
- 15.4 Beijing Minhai Biotechnology
- 15.5 GlaxoSmithKline Biologicals
- 15.6 Merck & Co, Inc
- 15.7 CSL Ltd.
- 15.8 Sinovac Biotech
- 15.9 Pfizer Inc.
- 15.10 Sanofi Pasteur
- 15.11 Serum Institute of India
- 15.12 Emergent Biosolutions
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
